Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

TCGA-CF-A27C-01A-11R-A16R-07

00846900-421c-50cb-8701-cf6d6f8db8b2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
overall_survival_months
13.96189225
os_event
false
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.100
  • PEROXISOME+0.040
  • ESTROGEN_RESPONSE_EARLY+0.000
  • BILE_ACID_METABOLISM-0.070
  • ESTROGEN_RESPONSE_LATE-0.070
  • MYC_TARGETS_V2-0.070
  • PROTEIN_SECRETION-0.070
  • ANDROGEN_RESPONSE-0.080
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.080
  • SPERMATOGENESIS-0.090

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
  • E2F_TARGETS-0.520
  • INFLAMMATORY_RESPONSE-0.490
  • TNFA_SIGNALING_VIA_NFKB-0.490
  • ANGIOGENESIS-0.460
  • G2M_CHECKPOINT-0.430
  • ALLOGRAFT_REJECTION-0.420
  • IL2_STAT5_SIGNALING-0.420
  • MTORC1_SIGNALING-0.390
  • HEDGEHOG_SIGNALING-0.380

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1R247
bladder-landscape@3
0.920
2TCGA-CF-A5U8-01A-11R-A28M-07
bladder-landscape@3
0.904
3SRR8943008
bladder-landscape@3
0.903
4EPT0291
medullo-epn-umap@date-based
EPNEPN Tumor0.896
5TCGA-FD-A43X-01A-11R-A23W-07
bladder-landscape@3
0.890
6SRR23303775
bladder-landscape@3
0.886
7SRR650197
bladder-landscape@3
0.886
8TCGA-LT-A8JT-01A-11R-A36F-07
bladder-landscape@3
0.885
9C3N-03420
lung-landscapes@6
cohortA10.883
10SRR12202498
bladder-landscape@3
0.882

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 2 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.100Remibrutinib— uncovered
PEROXISOME0.040Idelalisib— uncovered